Introduction Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and chronic ...

Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...

In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against the other stocks. Wall Street's major indices kicked off the trading on a positive note ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) shares traded down 4.9% on Monday after Maxim Group lowered their price target on the stock from $120.00 to $70.00.Maxim Group currently ...

Research analysts anticipate that Viking Therapeutics will post -1.41 EPS for the current fiscal year. Several hedge funds have recently bought and sold shares of VKTX. Blue Trust Inc. acquired a ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

We recently published an article titled These 10 Companies Led Monday's Downturn. In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against the other ...

Viking Therapeutics VKTX has outperformed the market over the past 5 years by 22.07% on an annualized basis producing an ...

Fintel reports that on February 7, 2025, Citigroup initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Neutral ...